Table 3.
Percentage Change (95% CI) in Total 25(OH)D Associated With an IQR Increase in Urinary Phthalate Metabolite and BPA Concentrations Among U.S. Adults (≥20 Years Old), NHANES 2005–2010
| Urinary Analyte | Overall Population (n = 4667 Observations) |
Females (n = 2390 Observations) |
Males (n = 2277 Observations) |
|||
|---|---|---|---|---|---|---|
| %Δ (95% CI) | P Value | %Δ (95% CI) | P Value | %Δ (95% CI) | P Value | |
| MEHP | −2.07 (−3.62, −0.52) | .01a | −2.65 (−5.41, 0.12) | .07 | −1.46 (−3.14, 0.22) | .10 |
| MEHHP | −2.09 (−3.87, −0.32) | .03a | −2.00 (−4.57, 0.58) | .14 | −2.01 (−4.44, 0.41) | .11 |
| MEOHP | −1.66 (−3.40, 0.09) | .07 | −1.74 (−4.48, 0.99) | .22 | −1.37 (−3.53, 0.80) | .22 |
| MECPP | −1.88 (−3.77, 0.01) | .06 | −2.28 (−5.18, 0.62) | .13 | −1.33 (−3.56, 0.89) | .25 |
| ΣDEHP | −1.90 (−3.64, −0.17) | .04a | −2.08 (−4.74, 0.59) | .14 | −1.57 (−3.72, 0.58) | .16 |
| MBP | −0.11 (−2.21, 1.99) | .92 | 0.54 (−2.70, 3.78) | .75 | −0.72 (−3.37, 1.93) | .60 |
| MiBP | −1.67 (−3.74, 0.41) | .13 | −2.46 (−5.42, 0.50) | .11 | −0.99 (−4.13, 2.14) | .54 |
| MEP | 2.29 (0.91, 3.66) | <.01a | 3.72 (1.38, 6.06) | <.01a | 0.98 (−0.68, 2.63) | .26 |
| MBzP | 0.71 (−2.12, 3.54) | .63 | 0.02 (−3.91, 3.94) | .99 | 1.45 (−1.78, 4.69) | .38 |
| MCPP | 0.82 (−1.39, 3.02) | .47 | 1.34 (−2.43, 5.12) | .50 | 0.28 (−1.99, 2.54) | .81 |
| MCNP | 0.95 (−1.48, 3.39) | .45 | 1.03 (−2.79, 4.84) | .60 | 0.92 (−1.19, 3.02) | .40 |
| MCOP | −1.02 (−3.10, 1.06) | .34 | −1.05 (−4.29, 2.19) | .53 | −0.92 (−2.66, 0.82) | .31 |
| BPA | −1.30 (−3.02, 0.43) | .15 | −3.71 (−6.41, −1.02) | .01a | 0.88 (−3.01, 0.37) | .35 |
All linear regression models are weighted for complex survey design and adjusted for ln-transformed urinary creatinine, age, race/ethnicity, BMI, ln-transformed serum cotinine, sampling season, 30-day vitamin D supplement use, and survey cycle. Overall population models are additionally adjusted for gender.
a
P < .05.